41339-17-7

Basic information

• Product Name: 3-Amino-5-nitroindazole
• Synonyms: 3-AMINO-5-NITROINDAZOLE;5-NITRO-1H-INDAZOL-3-AMINE;3-Amino-5-nitro-1H-indazole;1H-indazol-3-amine, 5-nitro-;5-nitroindazol-3-aMine;5-Nitro-1H-indazol-3-ylaMine;1H-Indazole, 3-amino-5-nitro-
• CAS NO: 41339-17-7
• Molecular Formula: C₇H₆N₄O₂
• Molecular Weight: 178.15
• Product Categories: Indoles and derivatives
• Mol File: 41339-17-7.mol

Chemical Properties

• Melting Point: 254-256°C
• Boiling Point: 485.233 °C at 760 mmHg
• Flash Point: 247.26 °C
• Appearance: /
• Density: 1.631 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.817
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.60±0.40(Predicted)
• CAS DataBase Reference: 3-Amino-5-nitroindazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-5-nitroindazole(41339-17-7)
• EPA Substance Registry System: 3-Amino-5-nitroindazole(41339-17-7)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 41339-17-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Amino-5-nitroindazole is used as a key intermediate in the synthesis of drugs and other pharmacologically active substances. Its unique structure allows for the creation of a variety of compounds with potential therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-amino-5-nitroindazole is used as a research tool to explore the properties and potential uses of compounds derived from its structure. Its role in the development of new drugs and understanding molecular interactions is crucial.
Used in Chemical Intermediates Production:
3-Amino-5-nitroindazole is also used in the production of other chemical intermediates that are essential in the synthesis of complex molecules, including those with potential applications in the pharmaceutical industry.

InChI:InChI=1/C7H6N4O2/c8-7-5-3-4(11(12)13)1-2-6(5)9-10-7/h1-3H,(H3,8,9,10)

Upstream product

• 1219024-62-0 2-[2-(diphenylmethylene)hydrazino]-5-nitrobenzonitrile 
• 16588-02-6 4-chloro-3-cyanonitrobenzene 
• 17417-09-3 2-fluoro-5-nitrobenzonitrile 
• 874-05-5 3-aminoindazole 
• 60160-68-1 2-cyano-4-nitrophenylhydrazine 

Downstream Products

• 1041612-49-0 N,1-bis(4-methoxybenzyl)-5-nitro-1H-indazol-3-amine 
• 574729-25-2 tert-butyl 3-amino-5-nitro-1H-indazole-1-carboxylate 
• 91532-29-5 6-nitrobenzo[d][1,2,3]triazin-4(3H)-one 

Relevant articles and documents

Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele

RAS mutations are found in 30% of all human cancers, with KRAS the most frequently mutated among the three RAS isoforms (KRAS, NRAS, and HRAS). However, directly targeting oncogenic KRAS with small molecules in the nucleotide-binding site has been difficult because of the high affinity of KRAS for GDP and GTP. We designed an engineered allele of KRAS and a covalent inhibitor that competes for GTP and GDP. This ligand-receptor combination demonstrates that the high affinity of GTP and GDP for RAS proteins can be overcome with a covalent inhibitor and a suitably engineered binding site. The covalent inhibitor irreversibly modifies the protein at the engineered nucleotide-binding site and is able to compete with GDP and GTP. This provides a new tool for studying KRAS function and suggests strategies for targeting the nucleotide-binding site of oncogenic RAS proteins.

COMPOSITION FOR INDUCING CELL REPROGRAMMING

The present invention relates to a composition for inducing cell reprogramming. The indazole derivative compound contained in the composition of the present invention shows an improved biological profile and at the same time can perform efficient cell rep

NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF

The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Direct access to 3-aminoindazoles by Buchwald-Hartwig C-N coupling reaction

An efficient synthesis of various N-substituted 3-aminoindazoles using Buchwald-Hartwig C-N coupling reaction is described. Several parameters were varied, including the nature of the halogen atom and the protecting group of the starting materials, as well as the effects of the catalyst system, base, solvent, and reaction time. The efficiency of microwave versus conventional heating was also compared to test the outcome of the reaction. Thus, by applying this recent knowledge about metal-catalyzed aminations, an alternative for the direct synthesis of primary 3-aminoindazoles has been provided. Georg Thieme Verlag Stuttgart. New York.

Protein kinase affinity reagents based on a 5-aminoindazole scaffold

Affinity reagents that target protein kinases are powerful tools for signal transduction research. Here, we describe a general set of kinase ligands based on a 5-aminoindazole scaffold. This scaffold can readily be derivatized with diverse binding elements and immobilized analogs allow selective enrichment of protein kinases from complex mixtures.

Two-step synthesis of substituted 3-aminoindazoles from 2-bromobenzonitriles

A general two-step synthesis of substituted 3-aminoindazoles from 2-bromobenzonitriles involving a palladium-catalyzed arylation of benzophenone hydrazone followed by an acidic deprotection/cyclization sequence is described. This procedure offers a general and efficient alternative to the typical S NAr reaction of hydrazine with o-fluorobenzonitriles.

GLUCOKINASE ACTIVATORS

Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of wherein the variables are as defined herein.

Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists

The synthesis and biological evaluation of novel 3-amino indazole melanin concentrating hormone receptor-1 antagonists are reported, several of which demonstrated functional activity of less than 100 nM. Compounds 19 and 28, two of the more potent compounds identified in this study, were characterized by high exposure in the brain and demonstrated robust efficacy when dosed in diet-induced obese mice.

Indazole compounds useful as protein kinase inhibitors

The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative thereof, wherein R1, R2, V1, V2, and V3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT, PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.